LMNL — Liminal BioSciences Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $27.62m
- $14.21m
- CA$0.40m
Brief: Liminal Biosciences Reports Q3 Net Income Of $82.3 Mln Vs Year-Ago Loss Of $23.3 Mln
Liminal BioSciences Inc expected to post a loss of 34 cents a share - Earnings Preview
Liminal BioSciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Liminal Biosciences Reports Q2 Net Loss Of $32.1 Million
Liminal BioSciences Inc expected to post a loss of 53 cents a share - Earnings Preview
Liminal BioSciences Inc expected to post a loss of 53 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Moderna, Scworx, BioVie
U.S. STOCKS ON THE MOVE-Golden Nugget Online Gaming, Tyson Foods, Kaleyra
Liminal BioSciences surges on sale of priority review voucher
Brief: Liminal BioSciences Announces Sale Of Priority Review Voucher For $105 Mln
Liminal BioSciences Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Liminal BioSciences Announces Signature Of A Share Purchase Agreement
Liminal BioSciences: Surges after FDA approves genetic disorder drug
Brief: Liminal Biosciences Announces FDA Approval For Its Biologics License Application For Ryplazim (Plasminogen, Human-Tvmh)
NASDAQ TRADE HALT HALT NEWS PENDING AT 02:56 PM
U.S. RESEARCH ROUNDUP-Cloudera, Gap, Immunovant,
Liminal BioSciences: Down on cancelling some studies for drug candidate Fezagepras
Liminal BioSciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Liminal Biosciences Says Cash And Cash Equivalents On March 31 Was $21.6 Mln